Literature DB >> 1473549

Interferon alpha-2a therapy of consumptive coagulopathy in Kasabach-Merritt syndrome.

C Klein, M Hauser, H B Hadorn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1473549     DOI: 10.1007/bf01954133

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  7 in total

1.  Successful treatment of an angiogenic disease.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1989-05-04       Impact factor: 91.245

2.  Treatment of severe coagulopathy in the Kasabach-Merritt syndrome with aminocaproic acid and cryoprecipitate.

Authors:  R P Warrell; S J Kempin
Journal:  N Engl J Med       Date:  1985-08-01       Impact factor: 91.245

3.  Kasabach-Merritt syndrome: therapeutic considerations.

Authors:  E C Larsen; W H Zinkham; J C Eggleston; B J Zitelli
Journal:  Pediatrics       Date:  1987-06       Impact factor: 7.124

4.  Interferon enhances prostacyclin production by cultured vascular endothelial cells.

Authors:  A Eldor; R Fridman; I Vlodavsky; E Hy-Am; Z Fuks; A Panet
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

5.  High dose intravenous methylprednisolone for Kassabach-Merritt syndrome.

Authors:  S Ozsoylu; G Irken; A Gürgey
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

6.  Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a.

Authors:  C W White; S J Wolf; D N Korones; H M Sondheimer; M F Tosi; A Yu
Journal:  J Pediatr       Date:  1991-01       Impact factor: 4.406

7.  Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.

Authors:  R A Ezekowitz; J B Mulliken; J Folkman
Journal:  N Engl J Med       Date:  1992-05-28       Impact factor: 91.245

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.